Companies / Austria
More M&A For GSK
October 2008 | Company News AlertUK pharmaceutical firm GlaxoSmithKline (GSK) has reiterated its 'diversify to de-risk' strategy during October 2008 with three medium size acquisitions, all focused away from traditional blockbuster pharmaceuticals. BMI sees GSK's bold attitude towards coping with growing sector-specific pressures - such as patent expiries, faltering product pipelines and added requirements to demonstrate true product value - as well as the global economic slowdown, as a sign of strength from the world's second largest drugmaker. Furthermore, with over GBP5.1bn (US$7.9bn) of cash or cash equivalents on the balance sheet at the end of the third quarter of 2008 and CEO Andrew Witty
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
